Carboplatin+Paclitaxel

DRUG3 trials

Sponsors

West Japan Oncology Group, AstraZeneca

Conditions

Advanced Ovarian CancerNon-small-cell lung cancerThymic cancer

Phase 1

A phase I study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for stage III non-small cell lung cancer

Active, not recruitingJPRN-UMIN000001234

West Japan Oncology GroupNon-small-cell lung cancer

Start: 2006-04-01Target: 24Updated: 2026-06-29

Phase 2

A Phase II Study of carboplatin plus paclitaxel for advanced thymic cancer

Active, not recruitingJPRN-UMIN000001358

West Japan Oncology GroupThymic cancer

Start: 2008-05-01Target: 40Updated: 2026-06-29

Phase 3

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

Active, not recruitingNCT03737643

AstraZenecaAdvanced Ovarian Cancer

Start: 2019-01-04End: 2026-12-23Updated: 2026-07-07

Related Papers

Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.

2025-12-09

Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer.

2025-10-01

PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers

British Journal of Cancer2024-07-0617 citations

Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4

Nature Communications2023-09-0621 citations

#1120 Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour BRCA1/2 mutation: results from the DUO-O/ENGOT-Ov46/AGO-OVAR 23/GOG-3025 trial

2023-09-012 citations

Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.

Journal of Clinical Oncology2023-06-0750 citations

Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer

Scientific Reports2021-06-016 citations

DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.

Journal of Clinical Oncology2019-05-2046 citations